IN8bio announces The Ohio State University as a new site for its Phase 1 trial of gamma-delta T cell therapy INB-100.
Quiver AI Summary
IN8bio, Inc. has announced that The Ohio State University is now a clinical site for its Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia patients undergoing haploidentical stem cell transplantation. This addition highlights significant interest in INB-100 and aims to enhance patient enrollment for the trial, which investigates ways to minimize the risks of graft-versus-host disease and relapse after transplantation. Dr. Sarah A. Wall from Ohio State expressed enthusiasm about leading the trial, emphasizing the importance of haploidentical donors in improving access to transplants for under-represented groups. CEO William Ho noted that with multiple clinical sites involved, the company anticipates completing enrollment and sharing follow-up data in the coming year, as INB-100 shows promising outcomes for patients with complex, high-risk diseases.
Potential Positives
- The addition of The Ohio State University as a clinical site enhances the credibility and visibility of IN8bio's INB-100 trial.
- Increased enrollment capacity through new trial sites may accelerate the trial's progress and data collection.
- Positive early outcomes, such as long-term leukemic remissions and the absence of severe graft-versus-host disease in initial patients, support the potential effectiveness of INB-100.
- Engagement with a leading academic institution reflects strong interest in innovative cancer therapies and positions IN8bio at the forefront of clinical advancements in this area.
Potential Negatives
- There is no mention of successful past trial results for INB-100, which could lead to skepticism about the therapy's efficacy and safety among potential investors and stakeholders.
- The press release primarily focuses on the addition of a new clinical site rather than significant new findings, which may signal a lack of progress or slow enrollment in ongoing trials.
- While the addition of The Ohio State University is positive, the reliance on a single new site for a Phase 1 trial may indicate challenges in securing broader partnerships or sites, which could affect trial timelines and data collection.
FAQ
What is INB-100?
INB-100 is a donor-derived allogeneic gamma-delta T cell therapy for treating patients with leukemias undergoing haploidentical stem cell transplantation.
Which institution is the latest clinical site for the INB-100 trial?
The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of INB-100.
What are the main goals of the INB-100 trial?
The trial aims to evaluate the safety, durability, and anti-leukemic activity of INB-100 in the post-transplant setting.
Who is leading the INB-100 trial?
The trial is being led by Dr. Joseph P. McGuirk, a prominent figure in Hematology-Oncology at the Kansas University Cancer Center.
What potential benefits does INB-100 offer?
INB-100 may improve outcomes and reduce relapse rates in patients following stem cell transplantation, showing promising long-term survival outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INAB Hedge Fund Activity
We have seen 2 institutional investors add shares of $INAB stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC removed 189,873 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $396,834
- VANGUARD GROUP INC removed 60,099 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $125,606
- SIGMA PLANNING CORP removed 23,356 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $48,814
- ALYESKA INVESTMENT GROUP, L.P. added 13,165 shares (+19.0%) to their portfolio in Q2 2025, for an estimated $27,514
- NORTHERN TRUST CORP removed 3,114 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,508
- STATE STREET CORP removed 2,958 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,182
- XTX TOPCO LTD removed 2,324 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,857
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation.
The addition of this leading academic institution reflects a strong interest in INB-100 and supports the ongoing efforts to accelerate enrollment and complete this Phase 1 trial.
“This trial is an excellent opportunity to explore a strategy aimed at reducing the risk of graft-versus-host disease and the risk of relapse following haploidentical stem cell transplant,” said Sarah A. Wall, M.D., Investigator and Assistant Professor in the College of Medicine at The Ohio State University. “The increased use of haploidentical donors in the last decade has created more access to potentially life-saving allogeneic transplants for many patients, particularly under-represented groups who are less likely to have fully matched donors. I am incredibly excited to be opening and leading this trial at The James Comprehensive Cancer Center at Ohio State University.”
“We are excited to welcome The Ohio State University as a clinical partner in the INB-100 study,” said William Ho, CEO and co-founder of IN8bio. “With multiple sites actively screening, we look forward to completing the enrollment of the expansion cohort and providing follow-up data next year. INB-100 continues to demonstrate the potential of gamma-delta T cells to improve outcomes and reduce relapse in patients following stem cell transplantation. Multiple patients with complex, high-risk disease continue to demonstrate long-term leukemic remissions with the earliest treated patients now beyond four- and five-years relapse-free.”
The INB-100 trial is being run by Principal Investigator Dr. Joseph P. McGuirk, the Schutte-Speas Professor of Hematology-Oncology, Division Director, Hematologic Malignancies and Cellular Therapeutics, Medical Director, Blood and Marrow Transplant at the Kansas University Cancer Center (KUCC). The trial is designed to evaluate the safety, durability, and anti-leukemic activity of IN8bio’s allogeneic gamma-delta T cell therapy in the post-transplant setting. The Company has previously presented clinical data demonstrating encouraging long-term survival outcomes relative to real-world historical data, immune reconstitution including expansion and persistence of the allogenic INB-100 gamma-delta T cell therapy up to 1-year post treatment, and absence of severe graft-versus-host disease.
For more information about the study NCT03533816, visit clinicaltrials.gov
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com .
Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
[email protected]
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
[email protected]
